Treating Low-grade or Follicular Non-Hodgkin’s Lymphoma upon Relapse
RITUXAN® is indicated for the treatment of patients with relapsed or refractory, low-grade or follicular, CD20-positive, B-cell NHL as a single agent.
If low-grade or follicular (indolent) NHL relapses, RITUXAN® may help. For many people, RITUXAN may help reduce tumor size—even if they have large tumors.
In clinical studies, RITUXAN shrunk tumors significantly for many people whose NHL had relapsed. There were 4 separate studies (with 60, 166, 37, and 31 patients each). In one of the studies, RITUXAN was proven to shrink tumors in patients who had also been treated with RITUXAN earlier in the course of their disease.
The most common side effects when RITUXAN was given by itself included infusion reactions, fever, chills, infection, weakness, and decreased blood cell counts. Serious side effects included decreased blood cell counts, lung problems, and infection. RITUXAN can cause serious side effects, some of which can be life-threatening, including progressive multifocal leukoencephalopathy (PML), infusion reactions, tumor lysis syndrome (TLS), and severe skin reactions. Be sure to read the Medication Guide and full Prescribing Information before each RITUXAN treatment.
Watch a discussion about RITUXAN clinical trial results
How RITUXAN Is Given
To treat low-grade or follicular (indolent) NHL after a relapse, you may receive a RITUXAN infusion:
- Once weekly
- For 4 weeks or for 8 weeks
“My wife had encouraged me to start going to support groups early in the diagnosis, which I did and have continued to do through the years.” —Bill, RITUXAN patient
This information does not take the place of talking with your doctor. Discuss with your doctor any questions you have about your medical condition or your treatment.
INDICATIONS and IMPORTANT SAFETY INFORMATION
RITUXAN® is indicated for the treatment of patients with:
- Relapsed or refractory, low-grade or follicular, CD20-positive, B-cell NHL as a single agent
- Previously untreated follicular, CD20-positive, B-cell NHL in combination with CVP chemotherapy
- Non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL, as a single agent, after first-line CVP chemotherapy
- Previously untreated diffuse large B-cell, CD20-positive NHL in combination with CHOP or other anthracycline-based chemotherapy regimens
Important Safety Information
RITUXAN® can cause serious side effects, some of which can be life-threatening, including: progressive multifocal leukoencephalopathy (PML), infusion reactions, tumor lysis syndrome (TLS), and severe skin reactions. Other serious and life-threatening side effects with RITUXAN include: hepatitis B virus reactivation, heart problems, infections, and stomach and bowel problems. Common side effects during RITUXAN infusions include: fever, headache, chills and shakes, nausea, itching, hives, cough, sneezing, and throat irritation or tightness.
Tell your doctor about any side effects that bother you or that do not go away. These are not all of the possible side effects with RITUXAN. Ask your doctor for more information.
Please read the Medication Guide in HTML or PDF versions and the full prescribing information for more information.
